Juergen Froehlich

Dr. Froehlich’s career in biotechnology spans three decades and covers a broad range of drug development successes. It includes strategic planning and execution of early and late stage drug development and regulatory interactions across therapeutic areas such as cerebrovascular, cardiovascular, pulmonary, metabolic, genetic and infectious disorders. He has worked with biologics, peptides, small molecules and RNA therapeutics at companies including Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers-Squibb, Ipsen, Vertex, Aradigm and Genevant. Since 2005, he has mainly been involved with rare diseases including bronchiectasis, cystic fibrosis, non-tuberculous mycobacteria infection, acromegaly, neuroendocrine tumors, urea cycle disorders cervical dystonia and hemophilia. He was instrumental in obtaining successful marketing authorizations in the US, EMA and other countries for ODD designated products in cystic fibrosis, acromegaly and cervical dystonia. As Chief Medical Officer and Head of Regulatory Affairs of Aradigm Corporation, he initiated, oversaw, and completed a Phase 3 trial program with inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa lung infection. He was an invited panel member at a U.S. Food and Drug Administration (FDA) workshop in 2018 for inhaled antibiotics in cystic fibrosis and bronchiectasis.